Recombinant Human AGER Protein，His

AGER, or Advanced Glycation End-products Receptor, is a receptor that plays a significant role in various pathological processes, particularly in the context of diabetes, Alzheimer's disease, and other age-related disorders. The research background on AGER focuses on its involvement in the molecular mechanisms underlying chronic inflammation, oxidative stress, and tissue remodeling associated with these diseases. Elevated levels of advanced glycation end-products, which result from the non-enzymatic glycation of proteins and lipids, activate AGER signaling pathways. This activation has been implicated in promoting inflammatory responses and contributing to cellular dysfunction and apoptosis. Researchers have been investigating the potential of AGER as a therapeutic target for modulating these pathogenic processes. Studies have shown that inhibiting AGER or its ligands can reduce inflammation and improve metabolic outcomes in animal models. Furthermore, AGER's role in cognitive decline and neurodegenerative diseases has garnered attention, as its activation can exacerbateβ-amyloid plaque formation and tau phosphorylation, two hallmarks of Alzheimer's disease. The ongoing research aims to better understand AGER's diverse functions, explore its interactions with other signaling pathways, and develop AGER-based therapeutic approaches that could provide new strategies for treating age-related diseases and improving overall healthspan.